RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma
暂无分享,去创建一个
S. Awasthi | S. Singhal | P. Singhal | L. Nagaprashantha | Sulabh Singhal | J. Singhal | D. Horne | Sulabh S. Singhal
[1] J. George,et al. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. , 2017, Cancer research.
[2] A. Cañete,et al. Advances in emerging drugs for the treatment of neuroblastoma , 2017, Expert opinion on emerging drugs.
[3] A. Califano,et al. HAUSP deubiquitinated and stabilizes N-Myc in neuroblastoma , 2016, Nature Medicine.
[4] K. Matthay,et al. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. , 2016, European journal of cancer.
[5] Lian Chen,et al. Epidermal growth factor receptor is overexpressed in neuroblastoma tissues and cells. , 2016, Acta biochimica et biophysica Sinica.
[6] D. K. Lowe,et al. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma. , 2016, The Annals of pharmacotherapy.
[7] D. Dimitrov,et al. A dual‐specific anti‐IGF‐1/IGF‐2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma , 2015, International journal of cancer.
[8] S. Agarwal,et al. The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma , 2015, Cell Death Discovery.
[9] Zhenyu Zhu,et al. RLIP76 Blockade by siRNA Inhibits Proliferation, Enhances Apoptosis, and Suppresses Invasion in HT29 Colon Cancer Cells , 2015, Cell Biochemistry and Biophysics.
[10] J. Vincent,et al. Inhibitors of endocytosis prevent Wnt/Wingless signalling by reducing the level of basal β-catenin/Armadillo , 2014, Journal of Cell Science.
[11] Yuan Li,et al. Wnt inhibitory factor-1 functions as a tumor suppressor through modulating Wnt/β-catenin signaling in neuroblastoma. , 2014, Cancer letters.
[12] Zhuogang Liu,et al. Knockdown of RLIP76 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to daunorubicin in U937 leukemia cells , 2014, Tumor Biology.
[13] H. Mott,et al. Structure and function of RLIP76 (RalBP1): an intersection point between Ras and Rho signalling. , 2014, Biochemical Society transactions.
[14] R. Gabdoulline,et al. ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis , 2014, Cell Death and Differentiation.
[15] D. Nietlispach,et al. The Structure of the RLIP76 RhoGAP-Ral Binding Domain Dyad: Fixed Position of the Domains Leads to Dual Engagement of Small G Proteins at the Membrane , 2013, Structure.
[16] Seunghyung Lee,et al. Emerging treatments in lung cancer – targeting the RLIP76 molecular transporter , 2013, Lung Cancer.
[17] William A Weiss,et al. Neuroblastoma and MYCN. , 2013, Cold Spring Harbor perspectives in medicine.
[18] Zhongwei Lv,et al. RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis. , 2013, Carcinogenesis.
[19] M. Lodish. Kinase Inhibitors: Adverse Effects Related to the Endocrine System , 2013 .
[20] Juxiang Chen,et al. Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells , 2013, Journal of Neuro-Oncology.
[21] Tony T. Huang. Deubiquitinases as a signaling target of oxidative stress , 2012, Cell reports.
[22] S. Awasthi,et al. RALBP1/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neovascularization. , 2012, Cancer research.
[23] M. Koch,et al. Overexpression of RalBP1 in colorectal cancer is an independent predictor of poor survival and early tumor relapse , 2012, Cancer biology & therapy.
[24] S. Awasthi,et al. RLIP76 Regulates PI3K/Akt Signaling and Chemo-Radiotherapy Resistance in Pancreatic Cancer , 2012, PloS one.
[25] M. Rossner,et al. Regulation of the EGF Transcriptional Response by Endocytic Sorting , 2012, Science Signaling.
[26] W. Gu,et al. p53 regulation by ubiquitin , 2011, FEBS letters.
[27] U. Kees,et al. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63 , 2011, Oncogene.
[28] R. Vatsyayan,et al. Targeting p53-Null Neuroblastomas through RLIP76 , 2011, Cancer Prevention Research.
[29] Sumihiro Suzuki,et al. Glutathione-Conjugate Transport by RLIP76 Is Required for Clathrin-Dependent Endocytosis and Chemical Carcinogenesis , 2011, Molecular Cancer Therapeutics.
[30] M. Conaway,et al. RalBP1 is necessary for metastasis of human cancer cell lines. , 2010, Neoplasia.
[31] M. Barton,et al. Making sense of ubiquitin ligases that regulate p53 , 2010, Cancer biology & therapy.
[32] R. Vatsyayan,et al. Mechanisms of 4-hydroxy-2-nonenal induced pro- and anti-apoptotic signaling. , 2010, Biochemistry.
[33] R. Vatsyayan,et al. RLIP76: a versatile transporter and an emerging target for cancer therapy. , 2010, Biochemical pharmacology.
[34] N. Cheung,et al. Neuroblastoma: Therapeutic strategies for a clinical enigma. , 2010, Cancer treatment reviews.
[35] M. Kubota,et al. Mortality and morbidity of patients with neuroblastoma who survived for more than 10 years after treatment--Niigata Tumor Board Study. , 2010, Journal of pediatric surgery.
[36] M. Lovell,et al. Primary pancreatic neuroblastoma: an unusual tumor in infancy. , 2010, Journal of pediatric surgery.
[37] Joana M. Xavier,et al. The role of p53 in apoptosis. , 2010, Discovery medicine.
[38] J. Leavitt,et al. Incidence of pediatric Horner syndrome and the risk of neuroblastoma: A population-based study , 2010 .
[39] R. Vatsyayan,et al. A Central Role of RLIP76 in Regulation of Glycemic Control , 2009, Diabetes.
[40] Lawrence A. Donehower,et al. 20 years studying p53 functions in genetically engineered mice , 2009, Nature Reviews Cancer.
[41] R. Vatsyayan,et al. Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis. , 2009, Cancer letters.
[42] A. Sorkin,et al. Endocytosis and signalling: intertwining molecular networks , 2009, Nature Reviews Molecular Cell Biology.
[43] R. Vatsyayan,et al. Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer , 2009, International journal of cancer.
[44] Xi He,et al. Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.
[45] Andrea C. Carrano,et al. A conserved ubiquitination pathway determines longevity in response to diet restriction , 2009, Nature.
[46] R. Vatsyayan,et al. Role of RLIP76 in doxorubicin resistance in lung cancer. , 2009, International journal of oncology.
[47] Y. Awasthi,et al. RLIP76: a target for kidney cancer therapy. , 2009, Cancer research.
[48] S. Awasthi,et al. Regression of prostate cancer xenografts by RLIP76 depletion. , 2009, Biochemical pharmacology.
[49] S. Singhal,et al. RLIP76: A novel glutathione-conjugate and multi-drug transporter. , 2009, Biochemical pharmacology.
[50] K. Matthay,et al. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. , 2008, Neoplasia.
[51] M. Sahu,et al. Diminished drug transport and augmented radiation sensitivity caused by loss of RLIP76 , 2008, FEBS letters.
[52] Jesse D. Martinez,et al. Hsf1 is required for the nuclear translocation of p53 tumor suppressor. , 2008, Neoplasia.
[53] Sumihiro Suzuki,et al. RLIP76 in defense of radiation poisoning. , 2008, International journal of radiation oncology, biology, physics.
[54] Y. Awasthi,et al. RLIP76 and Cancer , 2008, Clinical Cancer Research.
[55] Y. Awasthi,et al. Self-regulatory role of 4-hydroxynonenal in signaling for stress-induced programmed cell death. , 2008, Free radical biology & medicine.
[56] S. Awasthi,et al. Hsf-1 and POB1 Induce Drug Sensitivity and Apoptosis by Inhibiting Ralbp1* , 2008, Journal of Biological Chemistry.
[57] J. Maris,et al. Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification , 2008, Oncogene.
[58] A. Gudkov,et al. p53 determines multidrug sensitivity of childhood neuroblastoma. , 2007, Cancer research.
[59] D. Theodorescu,et al. Mass spectroscopic phosphoprotein mapping of Ral binding protein 1 (RalBP1/Rip1/RLIP76). , 2007, Biochemical and biophysical research communications.
[60] D. Theodorescu,et al. Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer , 2007, Clinical Cancer Research.
[61] P. Boor,et al. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1). , 2007, Cancer research.
[62] Y. Awasthi,et al. Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. , 2007, International journal of oncology.
[63] J. Shabanowitz,et al. RLIP76 (RalBP1) is an R-Ras effector that mediates adhesion-dependent Rac activation and cell migration , 2006, The Journal of cell biology.
[64] I. Watson,et al. Ubiquitin and ubiquitin-like modifications of the p53 family. , 2006, Neoplasia.
[65] R. Nusse,et al. BMC Cell Biology BioMed Central Research article , 2006 .
[66] Y. Awasthi,et al. Regression of melanoma in a murine model by RLIP76 depletion. , 2006, Cancer research.
[67] P. Dent,et al. RLIP76 is a major determinant of radiation sensitivity. , 2005, Cancer research.
[68] Y. Awasthi,et al. POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis. , 2005, Biochemical and biophysical research communications.
[69] Jeffrey L. Wrana,et al. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling , 2005, Nature Reviews Molecular Cell Biology.
[70] Y. Awasthi,et al. Regulation of 4-hydroxynonenal-mediated signaling by glutathione S-transferases. , 2004, Free radical biology & medicine.
[71] G. Werther,et al. Neuronal protection from glucose deprivation via modulation of glucose transport and inhibition of apoptosis: a role for the insulin-like growth factor system , 2004, Brain Research.
[72] Y. Awasthi,et al. Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): A novel link between G‐protein and tyrosine kinase signaling and drug resistance , 2003, International journal of cancer.
[73] C. Rossé,et al. RLIP, an Effector of the Ral GTPases, Is a Platform for Cdk1 to Phosphorylate Epsin during the Switch Off of Endocytosis in Mitosis* , 2003, Journal of Biological Chemistry.
[74] L. Boni,et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[75] N. Mivechi,et al. HSF-1 Interacts with Ral-binding Protein 1 in a Stress-responsive, Multiprotein Complex with HSP90 in Vivo * , 2003, The Journal of Biological Chemistry.
[76] T. Triche,et al. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. , 2000, Medical and pediatric oncology.
[77] J. Camonis,et al. RLIP76, an effector of the GTPase Ral, interacts with the AP2 complex: involvement of the Ral pathway in receptor endocytosis. , 2000, Journal of cell science.
[78] Y. Awasthi,et al. Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. , 2000, Biochemistry.
[79] F. Berthold,et al. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. , 2000, Drugs.
[80] Abraham Weizman,et al. Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture. , 1999, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[81] D. Stram,et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. , 1999, Journal of pediatric hematology/oncology.
[82] L. Neckers,et al. In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome , 1998, Oncogene.
[83] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[84] J. Benítez,et al. Correlation between mutations in p53 gene and protein expression in human lymphomas , 1997, American journal of hematology.
[85] Park Sh,et al. A putative effector of Ral has homology to Rho/Rac GTPase activating proteins. , 1995 .
[86] Lawrence A. Donehower,et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.
[87] J. Camonis,et al. Bridging Ral GTPase to Rho Pathways , 1995, The Journal of Biological Chemistry.
[88] S. Cantor,et al. Identification and Characterization of Ral-Binding Protein 1, a Potential Downstream Target of Ral GTPases , 2022 .
[89] S. Srivastava,et al. Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. , 1994, The Journal of clinical investigation.
[90] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[91] M. White,et al. Insulin receptors internalize by a rapid, saturable pathway requiring receptor autophosphorylation and an intact juxtamembrane region , 1991, The Journal of cell biology.
[92] H. Varmus,et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.
[93] J. H. Wright. NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED , 1910, The Journal of experimental medicine.
[94] X. Liu,et al. RLIP76 expression as a prognostic marker of breast cancer. , 2015, European review for medical and pharmacological sciences.
[95] C. Der,et al. Activation and involvement of Ral GTPases in colorectal cancer. , 2011, Cancer research.
[96] M. Sahu,et al. Functional reconstitution of RLIP76 catalyzing ATP-dependent transport of glutathione-conjugates. , 2009, International journal of oncology.
[97] P. Dent,et al. Is a Major Determinant of Radiation Sensitivity , 2005 .
[98] L. Malerød,et al. Clathrin-dependent endocytosis. , 2004, The Biochemical journal.
[99] J. Hayes,et al. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. , 1995, Critical reviews in biochemistry and molecular biology.
[100] R. Weinberg,et al. A putative effector of Ral has homology to Rho/Rac GTPase activating proteins. , 1995, Oncogene.
[101] H. Esterbauer,et al. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. , 1991, Free radical biology & medicine.
[102] Ananda S. Prasad. Why a new hematology journal? , 1976 .